Complement C5 Inhibitor Zilucoplan Is Approved by FDA to Treat MG
UCB Pharma’s investigational agent zilucoplan, a complement C5 inhibitor, to treat patients with myasthenia gravis has been approved by the U.S. Food and Drug Administration under the market name Zilbrysq.
IVIG Reduces Infection Risk During Anti-BCMA Treatment for MM
Data suggests the bispecific BCMA-targeted antibody teclistamab may lead to grade 3 to 5 infections in as many as 44.8 percent of multiple myeloma patients, and hypogammaglobulinemia was noted in nearly 75 percent of patients.
Intranasal COVID-19 Vaccine Shows High Seroresponse
A Phase I randomized, double-blind, placebo-controlled dose-escalation study in healthy adults, called CDX-CoV-001, has found Codagenix’s intranasal COVID-19 vaccine candidate, CoviLiv, showed the vaccine had a high seroresponse rate and induced mucosal immunity in volunteers not previously vaccinated or infected.
Moderna’s Influenza-COVID-19 Vaccine Demonstrates Immunogenecity
Results from Moderna’s Phase I/II clinical trial that evaluated the safety and immunogenicity of its influenza-COVID-19 vaccine, mRNA 1083, showed immunogenicity against all four influenza strains compared to a standard dose of the influenza vaccine, Fluarix, in adults 50 to 64 years of age and against an enhanced influenza vaccine, Fluzone HD, in adults 65 to 79 years of age.
New mRNA-Based Therapy Effective in Treating Melanoma in Mouse Models
Investigators at the Icahn School of Medicine at Mount Sinai have designed an RNA-based strategy to activate dendritic cells, which play a key role in immune response, that eradicated tumors and prevented their recurrence in mouse models of melanoma.
Combination of IVIG and Corticosteroids Superior to Respective Monotherapies for Treatment of Relapsed ITP in Adults
The combination of intravenous immune globulin (IVIG) and corticosteroids is a more efficient and rapid treatment for relapsed immune thrombocytopenic purpura (ITP) in adults compared with the use of either therapy alone.
Early Albumin Administration May Reduce Mortality in Septic Shock and ARDS: Retrospective MIMIC III Database Study
A study has found that early albumin administration in septic shock patients with ARDS was independently associated with a reduction in 28-day mortality.
FDA Approves Antibody to Protect Infants Against RSV
The U.S. Food and Drug Administration (FDA) has approved nirsevimab to protect newborns from respiratory syncytial virus (RSV).
FDA Approves First Postpartum Depression Oral Treatment
The U.S. Food and Drug Administration has approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults.
Immunotherapy May Treat ALS, Says Study
A study led by scientists at Oregon Health & Science University has found that a type of monoclonal antibody already tested in certain forms of cancer may be a promising treatment in stopping the progression of amyotrophic lateral sclerosis (ALS).